The Micro-caps of today can become the Large-caps of tomorrow!

Two news items in this week's FT weekend have caught my eye. Firstly there is a full page article entitled "Pharma opens new front in war on cancer". The article is essentially suggesting that the big pharmas may be on the cusp of the biggest breakthrough in cancer therapy for decades, and goes on to describe how several companies including Bristol Myers Squibb, Roche, AstraZeneca, Merck and Glaxo are developing new block buster drugs which could be worth several billions of pounds in revenues should they prove successful.

First and foremost let's hope that most are successful, and that the breakthrough proves to be as exciting as oncologists believe it could be. These drugs could really open up a whole new front in the war on cancer, and potentially prolong and save the lives of many thousands of people.

From an investment point of view, if these companies are successful with their pipeline drugs then clearly their valuations will increase substantially by the boost to their earnings. However, there are a number of hurdles to overcome yet, and it's difficult to predict the potential winners from the also-rans.

It did get me thinking about a company I hold shares in though.

Angle at £35m, is a minnow in comparison to the pharmas mentioned above, but it's Parsortix device is potentially a pivotal tool in any big advances in fighting a whole range of cancers. A non-invasive (simple blood test) way of monitoring the effectiveness of existing and potential drugs (and combinations) in the war on cancer has got to be highly desirable.

A lack of newsflow in recent weeks has meant that Angle's share price has dipped from it's highs whilst the company awaits further feedback from Key Opinion Leaders. However, if the feedback for the Parsortix device continues to be favourable then I fully expect substantial sales to follow, and the share price to resume it's upward trajectory, although ultimately I expect the company to be bought out by one of the majors. Angle have already achieved CE approval for their device, and currently await FDA approval.

The FT Money section also includes a small article on insurance fraud. Most notable is a 34% rise this year in the number of bogus car insurance claims. In fact, motoring accounts for more than three-fifths of fraudulent insurance claims. How long before insurers insist on a Telematics black box in every car? Not long methinks. I'm hanging on tightly to my Trakm8 shares. Right place, at the right time? Here's hoping. Trakm8 is a profitable, cash generative company in a potentially explosive growth industry. The shares are very modestly priced given their prospects.

In a recent blog, I mentioned that buying shares in relatively illiquid small/micro-cap stocks required a "strong stomach" as price fluctuations are often quite severe. Trakm8 is a good example of this type of stock. In my experience, as a long term investor, if the story remains in tact, it's best just to buy and hold. The micro-caps of today can soon become the large-caps of tomorrow!!

Finally, talking of large -cap companies, John Lee has written a brief article in todays' FT and has mentioned that he recently bought shares in Morrison's based on a 6% yield, activist shareholder base and freehold property assets. John Lee is an excellent value investor and ISA millionaire.

If I was interested in an income based portfolio, I'd definitely be adding Morrison's, alongside Sainsbury's, Tesco, GlaxosmithKline and Direct Line. Quality companies which are highly unlikely to go bust anytime soon and pay dividends around the 5% mark.